NASDAQ: AVLNAvalyn Pharma Inc Stock
$29.84+0.35 (+1.19%)
Updated May 1, 2026
AVLN Price
$29.84
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$26.00
52 Week High
$30.20
P/E
-0.34x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$85.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.06
Operating Cash Flow
-$81M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVLN Overview
Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVLN's potential to beat the market
- AVLN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important AVLN news, forecast changes, insider trades & much more!
AVLN News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVLN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVLN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AVLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AVLN due diligence checks available for Premium users.
Valuation
AVLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.34x
Industry
29.05x
Market
18.83x
AVLN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AVLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$148.9M
Liabilities
$15.3M
Debt to equity
-0.06
AVLN's short-term assets ($143.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVLN's short-term assets ($143.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
AVLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Avalyn Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.